Mass. Movers

EU panel supports OK of Aegerion drug

Shares of Cambridge’s Aegerion Pharmaceuticals Inc. rose after the company said that a European Union advisory panel recommended its drug be approved as a treatment for a rare inherited disease that causes high levels of bad cholesterol. Regulators are expected to make a decision in the third quarter. The pill, Lojuxta, is intended to be used along with a low-fat diet and other methods intended to reduce bad LDL cholesterol. US regulators approved the drug in December. Here, it is marketed under the name Juxtapid.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of